📣Starting Session 19: “Advances in Immuno-oncology Therapy with Small Molecule Inhibitors” in Auditorium Capitalis with a lecture from Dr Murali RAMACHANDRA on “Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins” #EFMCISMC24 #MedChem

#HealthForAll Indian Council of Medical Research ICMR Signs Memorandum of Agreements with Industry and Academic Partners to Advance First-in-Human Phase 1 Clinical Trials. A key milestone in the pursuit of affordable and accessible cutting-edge treatments for all

With great pleasure, we announce the formalization of our Memorandum of Agreement (MoA) with ICMR for a collaborative research project, aimed at advancing our small molecule Multiple Myeloma clinical trial. business-standard.com/health/icmr-to… #OncologyCollaborations #OncologyPipeline

The formalization of our Memorandum of Agreement (MoA) with ICMR as highlighted by PIB India 🤝 #Cancer #Oncology #OncologyCollaborations #OncologyPipeline #CancerDrugs #DrugDiscovery

🎗🌸 October is Breast Cancer Awareness Month and ‘Awareness Is The First Step To Prevention’🌸🎗 🎗🌸At Aurigene Oncology Ltd we stand with millions of women and men around the world in the fight against Breast Cancer🌸🎗 #BreastCancerAwareness #BreastCancerAwarenessMonth

#JustIn | Dr Reddy’s arm Aurigene Oncology announces phase 1 results for Ribrecabtagene Autoleucel from SWASTH study. Drugs Controller General of India (DCGI) gives nod to commence phase 2 part of the trial

We are at CPHI at Milan in Italy. Our team representing Dr. Reddy's Active Pharmaceutical Ingredients, formulations, Biologics, CRDMO-Aurigene Pharmaceutical Services Limited and oncology drug discovery-Aurigene Oncology Limited are present and happy to discuss how we can

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma dlvr.it/TF71qC

Dr. Reddy’s Laboratories subsidiary Aurigene Oncology has received the Drugs Controller General of India’s (DCGI) nod to commence Phase 2 trial for Ribrecabtagene autoleucel , its novel autologous CAR-T cell therapy for multiple myeloma. trib.al/SZ0aB3y

Aurigene Oncology Ltd announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma #AurigeneOncology Dr. Reddy’s Laboratories Ltd equitybulls.com/category.php?i…

🎗October is #BreastCancerAwarenessMonth and ‘Awareness Is The First Step To #Prevention'🎗 Together we can make a difference by: 🌸 Raising awareness 🌸 Supporting research 🌸 Encouraging regular screenings #BreastCancerAwareness #BreastCancer #Cancer #Oncology #WomensHealth

October is #BreastCancerAwarenessMonth. Let’s raise #awareness and advance progress in #BreastCancerResearch and care. 🎗️Get Screened: Early detection saves life 🎗️Spread the word: Share authentic facts and resources 🎗️Support Survivors: Support those battling #BreastCancer